Trials / Completed
CompletedNCT05517512
Relation Between Protein 13 and Gestational Hypertensive Disorder
Low Serum Pregnancy Protein 13 Early in Pregnancy Might Predict the Oncoming Gestational Hypertensive Disorders, Especially Early-onset Preeclampsia
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 138 (actual)
- Sponsor
- Benha University · Academic / Other
- Sex
- Female
- Age
- 21 Years – 33 Years
- Healthy volunteers
- —
Summary
the attendants of the clinic with a one-missed period (T0) underwent determination of baseline blood pressure (BP) measures and gave blood samples for estimation of levels of placental growth factor (PLGF), soluble fms-like tyrosine kinase-1 (sFlt-1) and pregnancy protein 13 (PP13). The same evaluation was repeated on the 6th, 24th, 32nd, and 36th gestational week (GW). Twenty non-pregnant women gave samples as a negative control group.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Estimation of Protein 13 | Serum biomarkers' levels were measured using enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's instructions and were read using a 96 well microplate ELISA reader (Dynatech. MR 7000) 1. Human placental growth factor (PLGF) was measured with the enzyme-linked immunoassay (ELISA) kit (catalog no. DPG00 SPG00 PDPG00, R\&D Systems Inc., Minneapolis, USA) by quantitative sandwich enzyme immunoassay technique (20). 2. Human soluble fms-like tyrosine kinase-1 (sFlt-1) was measured with the enzyme-linked immunoassay (ELISA) kit (catalog no. MBS601616, MyBioSource, Inc., California, San Diego, USA) by quantitative sandwich enzyme immunoassay technique (21). 3. Human pregnancy protein 13 was measured with the enzyme-linked immunoassay (ELISA) kit (catalog no. ab100553, Abcam Inc., Cambridge, USA) by quantitative sandwich enzyme immunoassay technique (22). |
Timeline
- Start date
- 2020-03-12
- Primary completion
- 2021-03-14
- Completion
- 2022-03-19
- First posted
- 2022-08-26
- Last updated
- 2022-08-26
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT05517512. Inclusion in this directory is not an endorsement.